Brought to you by 
Atrium gets rights to Isotechnika's TAFA93, ISA247
15 May 2012
Executive Summary
Atrium Medical (cardiovascular therapeutics) has licensed exclusive worldwide rights to use Isotechnika's (autoimmune diseases) TAFA93 and ISA247 with its own drug eluting devices to nonsystemically treat vascular, cardiovascular, vessel, and tissue disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Atrium gets rights to Isotechnika's TAFA93, ISA247
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice